← Back to Clinical Trials
Recruiting NCT06560398

NCT06560398 Working Through Outreach, Navigation and Digital Enabled Referral and Recruitment Strategies (ACT WONDER²S)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06560398
Status Recruiting
Phase
Sponsor H. Lee Moffitt Cancer Center and Research Institute
Condition Cancer
Study Type INTERVENTIONAL
Enrollment 7,649 participants
Start Date 2024-09-18
Primary Completion 2026-09-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Continuing Medical Education Events (CME)Trial Connect PortalClinical Trial Newsletters

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 7,649 participants in total. It began in 2024-09-18 with a primary completion date of 2026-09-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of the study is to refine, finalize, implement, and evaluate a multi-level intervention aimed at increasing enrollment of Black and Hispanic patients to National Cancer Institute (NCI)-sponsored therapeutic clinic trials at Moffitt Cancer Center.

Eligibility Criteria

Inclusion Criteria: * Community residents: Community residents may engage with various intervention components deployed in the intervention priority zones. * Community Physicians: may engage with various intervention components deployed in the intervention priority zones if they 1) practice medicine in one of the geographic priority zones. * Cancer Center Physicians: may engage with various intervention components if they 1) practice medicine at Moffitt. * Clinical Research Coordinators (CRC): may engage with various intervention components if they 1) work as a CRC at Moffitt and 2) coordinate/pre-screen patients for at least 1 therapeutic clinical trial at Moffitt. * Cancer Center Patients: may engage with various intervention components if they have an address that maps to an intervention priority zone and 2) are newly registered patients or new existing patients (NEPs). Exclusion Criteria: * Community residents, Community Physicians, Cancer Center Physicians, Clinical Research Coordinators, and Moffitt patients who do not meet the inclusion criteria.

Contact & Investigator

Central Contact

Rossybelle Amorrortu, MPH

✉ Rossybelle.Amorrortu@moffitt.org

📞 813-745-4007

Principal Investigator

Susan Vadaparampil, PhD

PRINCIPAL INVESTIGATOR

Moffitt Cancer Center

Frequently Asked Questions

Who can join the NCT06560398 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06560398 currently recruiting?

Yes, NCT06560398 is actively recruiting participants. Contact the research team at Rossybelle.Amorrortu@moffitt.org for enrollment information.

Where is the NCT06560398 trial being conducted?

This trial is being conducted at Tampa, United States.

Who is sponsoring the NCT06560398 clinical trial?

NCT06560398 is sponsored by H. Lee Moffitt Cancer Center and Research Institute. The principal investigator is Susan Vadaparampil, PhD at Moffitt Cancer Center. The trial plans to enroll 7,649 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology